JUL 30, 2015 12:08 PM PDT

Tumor Shrinking Tactic

WRITTEN BY: Ilene Schneider
The most common type of lung cancer, which is also the most common cause of cancer deaths, is resistant to a cytokine called TRAIL that causes cell death in many other types of tumors, according to two papers released in the journal Proceedings of the National Academy of Sciences (PNAS) and reported in Drug Discovery & Development. A research team from the Cancer Research UK Manchester Institute in the United Kingdom examined the reasons for this problem (https://www.dddmag.com/news/2015/07/overcoming-why-new-treatment-resisted-lung-cancer?et_cid=4700013&et_rid=45505806&location=top).
UK researchers make cytokine work for benefit of shrinking NSCLC tumors.
Led by Dr. Michela Garofalo, the researchers determined that in non-small cell lung cancer, “a small RNA molecule called miR-148a is suppressed in TRAIL resistant cells, but when used together, miR-148a sensitizes tumor cells to TRAIL and results in the tumor shrinking.” Dr Garofalo added, “Discovering a potential reason why TRAIL is resisted by lung cancer could lead us to new treatments for this particularly deadly form of the disease. The miR-148a molecule certainly seems to play a role in this resistance, so it’s an avenue to explore alongside other factors which influence how the tumors respond to treatment.”

According to the American Cancer Society, about 85% to 90% of lung cancers are non-small cell lung cancer (NSCLC). The three main subtypes of NSCLC include cells that differ in size, shape, and chemical makeup when viewed under a microscope, but the approach to treatment and prognosis are similar. About 25 to 30 percent of all lung cancers are squamous cell carcinomas, which are often linked to a history of smoking and tend to be found in the middle of the lungs, near a bronchus. Approximately 40 percent of lung cancers are adenocarcinomas, which start in early versions of the cells that would normally secrete substances such as mucus, grow fairly slowly, occur in smokers and non-smokers, are more common in women and are more likely to occur in younger people than other types of lung cancer. Large cell (undifferentiated) carcinoma, which accounts for about 10 to 15 percent of lung cancers, can appear in any part of the lung and tends to grow and spread quickly, which can make it harder to treat (https://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer).

In related research that was also published in PNAS, Dr Garofalo’s team uncovered an additional mechanism that renders tumors resistant to TRAIL. NF-κB is a protein of which TRAIL itself increases the supply in resistant lung tumors. When the researchers suppressed the protein in cells, they determined that TRAIL became much more effective at making tumor cells die.

Dr. Garofalo concluded, “TRAIL is currently in clinical trials for other cancer types, but little is known about why non-small cell lung cancer is so resistant. These findings begin to shed light on those unique reasons, and suggest that by inhibiting the factors that cause resistance, TRAIL might become a useful treatment.”
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
APR 30, 2020
Cancer
APR 30, 2020
A New microRNA for the Cancer Fighting Toolkit
MiRNAs are small snippets of genetic information that regulate gene expression thought to be able to regulate up to 60% ...
MAY 21, 2020
Cancer
MAY 21, 2020
When is the best time to talk about end-of-life decisions with your teen who has cancer?
A study published recently in JAMA Network highlights the need for improved pediatric advanced care for adolescents with ...
MAY 26, 2020
Clinical & Molecular DX
MAY 26, 2020
Nanoengineering Aids Bladder Cancer Detection
   
JUN 11, 2020
Cancer
JUN 11, 2020
Fighting Cancer Stem Cells with Combination Therapy
Pancreatic cancer is one of the most fatal cancers in the United States and is rapidly advancing up the ranks. The best ...
JUN 09, 2020
Cancer
JUN 09, 2020
Genetic counseling for prostate cancer testing goes telehealth
Genetic testing for prostate cancer in men is not yet commonplace, despite the positive impact that it could have on dec ...
JUN 13, 2020
Cancer
JUN 13, 2020
Examining Cancers Effect on the Immune System for Prognostic Use
Most think of cancer in the context of where it is on the body like breast or pancreatic cancer. There are several more ...
Loading Comments...